Atossa Therapeutics Inc (ATOS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2020 | 12-2019 | 09-2019 | 06-2019 | 03-2019 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -2,947 | -17,240 | -14,622 | -11,336 | -4,073 |
| Depreciation Amortization | 12 | 53 | 40 | 28 | 14 |
| Accounts payable and accrued liabilities | 63 | -60 | 148 | -35 | 111 |
| Other Working Capital | -508 | -791 | 67 | -685 | -107 |
| Other Operating Activity | 150 | 8,910 | 7,946 | 7,377 | 1,907 |
| Operating Cash Flow | $-3,230 | $-9,128 | $-6,420 | $-4,651 | $-2,149 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | -8 | -8 | -8 | N/A |
| Investing Cash Flow | $N/A | $-8 | $-8 | $-8 | $N/A |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | N/A | 11,337 | 11,337 | 11,337 | 11,337 |
| Financing Cash Flow | $N/A | $11,337 | $11,337 | $11,337 | $11,337 |
| Beginning Cash Position | 12,691 | 10,491 | 10,491 | 10,491 | 10,491 |
| End Cash Position | 9,461 | 12,691 | 15,400 | 17,169 | 19,678 |
| Net Cash Flow | $-3,230 | $2,201 | $4,909 | $6,678 | $9,188 |
| Free Cash Flow | |||||
| Operating Cash Flow | -3,230 | -9,128 | -6,420 | -4,651 | -2,149 |
| Capital Expenditure | N/A | -8 | -8 | -8 | N/A |
| Free Cash Flow | -3,230 | -9,136 | -6,428 | -4,659 | -2,149 |